We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

61 hedge funds and large institutions have $113M invested in Acumen Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

2% more funds holding

Funds holding: 60 → 61 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.84% less ownership

Funds ownership: 71.48% → 67.65% (-3.8%)

23% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 22

27% less call options, than puts

Call options by funds: $206K | Put options by funds: $284K

29% less capital invested

Capital invested by funds: $158M → $113M (-$45.2M)

Holders
61
Holders Change
+1
Holders Change %
+1.67%
% of All Funds
0.97%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
10
Increased
17
Reduced
22
Closed
9
Calls
$206K
Puts
$284K
Net Calls
-$78K
Net Calls Change
-$401K

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$954K
2
JGC
J. Goldman & Co
New York
+$705K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$611K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$349K
5
Jane Street
Jane Street
New York
+$336K

Top Sellers

Rank Fund Capital Flow
1
PFO
Pathstone Family Office
New Jersey
-$3.49M
2
BlackRock
BlackRock
New York
-$2.47M
3
PA
Perceptive Advisors
New York
-$1.88M
4
GPC
Guardian Point Capital
Virginia
-$888K
5
SCM
Silverarc Capital Management
Massachusetts
-$774K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$39.7M – – –
DTC
2
Deep Track Capital
Connecticut
$16M – – –
SCV
3
Sands Capital Ventures
Virginia
$13.9M – – –
KIA
4
Knollwood Investment Advisory
Maryland
$6.81M – – –
LCM
5
Laurion Capital Management
New York
$4.9M – – –
GPP
6
Great Point Partners
Connecticut
$4.27M -$341K -65,314 -6%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.98M +$98.7K +18,900 +3%
BlackRock
8
BlackRock
New York
$2.73M -$2.47M -473,056 -41%
Millennium Management
9
Millennium Management
New York
$2.62M -$104K -19,833 -3%
DCM
10
Driehaus Capital Management
Illinois
$2.23M -$70.6K -13,515 -2%
WP
11
Woodline Partners
California
$1.73M – – –
CC
12
Commodore Capital
New York
$1.62M -$513K -98,315 -20%
PFO
13
Pathstone Family Office
New Jersey
$1.59M -$3.49M -668,600 -63%
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$1.45M +$611K +117,000 +49%
IC
15
Ikarian Capital
Texas
$1.04M – – –
Walleye Capital
16
Walleye Capital
New York
$798K +$954K +182,648 +1,315%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$677K – – –
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$650K -$426K -81,633 -34%
SCM
19
Silverarc Capital Management
Massachusetts
$597K -$774K -148,193 -50%
JGC
20
J. Goldman & Co
New York
$548K +$705K +135,000 New
GPC
21
Guardian Point Capital
Virginia
$528K -$888K -170,000 -57%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$527K +$210K +40,233 +45%
BCM
23
Bridgeway Capital Management
Texas
$478K +$179K +34,233 +41%
WP
24
WMS Partners
Maryland
$399K – – –
Jane Street
25
Jane Street
New York
$303K +$336K +64,343 +631%
1
2 3

ABOS Hedge Fund Activity: Q1 2023 in Review

61 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2023, worth a combined $113M — down 29% from $158M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ABOS positions and 9 closed out — a net gain of 1 holder — while 17 added to existing stakes and 22 trimmed.

The largest buyer was Walleye Capital, adding an estimated $954K. The largest seller was Pathstone Family Office, cutting an estimated $3.49M.

  • 61 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2023, up from 60 in Q4 2022.
  • Funds reported $113M of Acumen Pharmaceuticals stock for Q1 2023, down 29% quarter-over-quarter.
  • 10 funds opened new Acumen Pharmaceuticals positions in Q1 2023 and 9 closed out, a net change of +1 holder.
  • The largest Acumen Pharmaceuticals buyer in Q1 2023 was Walleye Capital, an estimated $954K added.
  • The largest Acumen Pharmaceuticals seller in Q1 2023 was Pathstone Family Office, an estimated $3.49M sold.

Based on aggregated 13F filings for Q1 2023.